Northwest Biotherapeutics, Inc.
NWBO
$0.25
$0.00-0.83%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 190.91% | -43.98% | -74.31% | 32.04% | -48.09% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 190.91% | -43.98% | -74.31% | 32.04% | -48.09% |
| Cost of Revenue | -47.22% | -8.36% | -10.41% | 5.15% | 41.17% |
| Gross Profit | 52.57% | 6.73% | 6.22% | -4.15% | -46.84% |
| SG&A Expenses | 5.06% | 0.60% | -22.74% | 15.45% | 0.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.31% | -4.21% | -17.05% | 10.34% | 20.16% |
| Operating Income | 27.00% | 3.25% | 15.37% | -9.95% | -22.17% |
| Income Before Tax | 103.02% | -38.48% | 13.94% | -5.63% | -101.92% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 104.92% | -38.48% | 13.94% | -5.63% | -101.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 104.92% | -38.48% | 13.94% | -5.63% | -101.92% |
| EBIT | 27.00% | 3.25% | 15.37% | -9.95% | -22.17% |
| EBITDA | 29.27% | 3.39% | 15.87% | -10.19% | -22.72% |
| EPS Basic | 112.76% | -17.42% | 26.49% | 9.43% | -58.06% |
| Normalized Basic EPS | 51.61% | -14.10% | 37.21% | 23.40% | -51.22% |
| EPS Diluted | 96.46% | 0.00% | 26.49% | 9.43% | -59.68% |
| Normalized Diluted EPS | 51.61% | -14.10% | 37.21% | 23.40% | -51.22% |
| Average Basic Shares Outstanding | 17.43% | 18.56% | 18.44% | 14.42% | 12.87% |
| Average Diluted Shares Outstanding | 17.43% | 18.56% | 18.44% | 14.42% | 12.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |